Compare Raymond James Financial, Inc. (RJF) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Raymond James Financial, Inc. is far larger — about 6× Travere Therapeutics Inc. Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.38% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RJF | TVTX | |
|---|---|---|
Market Cap | $30.15B | $5.02B |
Volume | 980,106 | 2,060,842 |
Sector | Financials | Health |
52-Week High | $181.18 | $67.52 |
52-Week Low | $140.89 | $26.79 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.02B | $5.15B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $156.78, down 1.18% with bearish technical indicators but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.14 exceeding expectations. Revenue growth has been steady from $10.9B in 2022 to $13.8B in 2025, with net income margins above 15%. Recent leadership transitions and PGA TOUR sponsorship highlight strategic developments.
The outlook remains positive with a $178.50 consensus price target representing 14% upside potential. Analyst consensus leans Hold (55.56%) with no Sell ratings, indicating cautious optimism. Key risks include volatile cash flows from investing activities and brokerage market sensitivity. The company's strong profitability metrics and institutional accumulation support long-term value.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
